The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms

Uffe V Schneider; Rikke Nielsen; Court Pedersen; Jesper Eugen-Olsen

doi:10.1186/1471-2334-7-134

The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms

Uffe V Schneider
, Rikke Nielsen
, Court Pedersen
, Jesper Eugen-Olsen

17 Citations (Scopus)

Abstract

High blood levels of soluble urokinase Plasminogen Activator Receptor (suPAR) are associated with poor outcomes in human immunodeficiency-1 (HIV-1) infected individuals. Research on the clinical value of suPAR in HIV-1 infection led to the development of the suPARnostic(R) assay for commercial use in 2006. The aim of this study was to: 1) Evaluate the prognostic value of the new suPARnostic assay and 2) Determine whether polymorphisms in the active promoter of uPAR influences survival and/or suPAR values in HIV-1 patients who are antiretroviral therapy (ART) naive.

Original language	English
Journal	BMC Infectious Disease
Volume	7
Issue number	1
Pages (from-to)	134
DOIs	https://doi.org/10.1186/1471-2334-7-134
Publication status	Published - 2007

Keywords

Adult
Antiretroviral Therapy, Highly Active
Biological Markers
Case-Control Studies
DNA, Viral
Denmark
Enzyme-Linked Immunosorbent Assay
Female
HIV Infections
HIV-1
Humans
Kaplan-Meier Estimate
Male
Polymorphism, Genetic
Polymorphism, Restriction Fragment Length
Predictive Value of Tests
Probability
Prognosis
Promoter Regions, Genetic
Receptors, Cell Surface
Receptors, Urokinase Plasminogen Activator
Retrospective Studies
Risk Assessment
Sensitivity and Specificity
Statistics, Nonparametric
Survival Analysis

Access to Document

10.1186/1471-2334-7-134

http://www.biomedcentral.com/1471-2334/7/134

Cite this

@article{b60d912681314f1d84d4ba56b37bd500,

title = "The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms",

abstract = "High blood levels of soluble urokinase Plasminogen Activator Receptor (suPAR) are associated with poor outcomes in human immunodeficiency-1 (HIV-1) infected individuals. Research on the clinical value of suPAR in HIV-1 infection led to the development of the suPARnostic(R) assay for commercial use in 2006. The aim of this study was to: 1) Evaluate the prognostic value of the new suPARnostic assay and 2) Determine whether polymorphisms in the active promoter of uPAR influences survival and/or suPAR values in HIV-1 patients who are antiretroviral therapy (ART) naive.",

keywords = "Adult, Antiretroviral Therapy, Highly Active, Biological Markers, Case-Control Studies, DNA, Viral, Denmark, Enzyme-Linked Immunosorbent Assay, Female, HIV Infections, HIV-1, Humans, Kaplan-Meier Estimate, Male, Polymorphism, Genetic, Polymorphism, Restriction Fragment Length, Predictive Value of Tests, Probability, Prognosis, Promoter Regions, Genetic, Receptors, Cell Surface, Receptors, Urokinase Plasminogen Activator, Retrospective Studies, Risk Assessment, Sensitivity and Specificity, Statistics, Nonparametric, Survival Analysis",

author = "Schneider, \{Uffe V\} and Rikke Nielsen and Court Pedersen and Jesper Eugen-Olsen",

year = "2007",

doi = "10.1186/1471-2334-7-134",

language = "English",

volume = "7",

pages = "134",

journal = "BMC Infectious Disease",

publisher = "BioMed Central Ltd",

number = "1",

}

TY - JOUR

T1 - The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms

AU - Schneider, Uffe V

AU - Nielsen, Rikke

AU - Pedersen, Court

AU - Eugen-Olsen, Jesper

PY - 2007

Y1 - 2007

N2 - High blood levels of soluble urokinase Plasminogen Activator Receptor (suPAR) are associated with poor outcomes in human immunodeficiency-1 (HIV-1) infected individuals. Research on the clinical value of suPAR in HIV-1 infection led to the development of the suPARnostic(R) assay for commercial use in 2006. The aim of this study was to: 1) Evaluate the prognostic value of the new suPARnostic assay and 2) Determine whether polymorphisms in the active promoter of uPAR influences survival and/or suPAR values in HIV-1 patients who are antiretroviral therapy (ART) naive.

AB - High blood levels of soluble urokinase Plasminogen Activator Receptor (suPAR) are associated with poor outcomes in human immunodeficiency-1 (HIV-1) infected individuals. Research on the clinical value of suPAR in HIV-1 infection led to the development of the suPARnostic(R) assay for commercial use in 2006. The aim of this study was to: 1) Evaluate the prognostic value of the new suPARnostic assay and 2) Determine whether polymorphisms in the active promoter of uPAR influences survival and/or suPAR values in HIV-1 patients who are antiretroviral therapy (ART) naive.

KW - Adult

KW - Antiretroviral Therapy, Highly Active

KW - Biological Markers

KW - Case-Control Studies

KW - DNA, Viral

KW - Denmark

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - HIV Infections

KW - HIV-1

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Polymorphism, Genetic

KW - Polymorphism, Restriction Fragment Length

KW - Predictive Value of Tests

KW - Probability

KW - Prognosis

KW - Promoter Regions, Genetic

KW - Receptors, Cell Surface

KW - Receptors, Urokinase Plasminogen Activator

KW - Retrospective Studies

KW - Risk Assessment

KW - Sensitivity and Specificity

KW - Statistics, Nonparametric

KW - Survival Analysis

U2 - 10.1186/1471-2334-7-134

DO - 10.1186/1471-2334-7-134

M3 - Journal article

C2 - 18021410

VL - 7

SP - 134

JO - BMC Infectious Disease

JF - BMC Infectious Disease

IS - 1

ER -

The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms

Abstract

Keywords

Access to Document

Fingerprint

Cite this